SGLT2 inhibitors improve cardiac function, reduce the progression of heart failure, and decrease cardiovascular risk in patients with type 2 diabetes mellitus.
Do SGLT2 inhibitors improve heart failure and left ventricular diastolic function parameters in patients with type 2 diabetes mellitus?
SGLT2 inhibitors improve cardiac function and reduce heart failure progression in patients with type 2 diabetes mellitus, supporting their cardioprotective role.
This article investigates the effects of SGLT2 inhibitors on heart failure and left ventricular diastolic function in patients with type 2 diabetes mellitus. The study analyzes the pathophysiological relationship between diabetes and cardiovascular complications, focusing on diabetic cardiomyopathy and diastolic dysfunction. The impact of SGLT2 inhibitors on cardiac remodeling, myocardial relaxation, and heart failure symptoms was evaluated using clinical and echocardiographic parameters. The findings indicate that SGLT2 inhibitors improve cardiac function, reduce the progression of heart failure, and decrease cardiovascular risk. The results confirm the cardioprotective potential of these agents and support their use in the comprehensive management of patients with type 2 diabetes mellitus
Tursunaliyev et al. (Fri,) conducted a review in Type 2 diabetes mellitus. SGLT2 inhibitors was evaluated on Heart failure and left ventricular diastolic function parameters. SGLT2 inhibitors improve cardiac function, reduce the progression of heart failure, and decrease cardiovascular risk in patients with type 2 diabetes mellitus.